Join Growin Stock Community!

Iridex corporationIRIX.US Overview

US StockHealthcare
(No presentation for IRIX)
My Watchlist

Ticker

Value

empty

There is no following symbol in this watchlist.

IRIX AI Insights

IRIX Overall Performance

IRIX AI Analysis & Strategy

AI Strategy

Browsing restrictions can be lifted for a fee.

IRIX Recent Performance

1.43%

Iridex corporation

0.05%

Avg of Sector

-0.31%

S&P500

IRIX PowerScanner

Introduction >>

Power Squeeze

Surfing Trend

1 Day

1 Week

1 Month

IRIX Key Information

IRIX Financial Forecast

chart

Browsing restrictions can be lifted for a fee.

QuarterlyEPS ForecastQoQMaxMin
2026Q1
2026Q2
2026Q3
2026Q4
2027Q1

IRIX Profile

IRIDEX Corporation, an ophthalmic medical technology company, provides therapeutic based laser systems, delivery devices, and consumable instrumentation to treat sight-threatening eye diseases in ophthalmology. It offers laser consoles, such as Cyclo G6 laser system for use in the treatment of glaucoma; IQ 532 and IQ 577 laser photocoagulation systems, which are used for the treatment of diabetic macular edema and other retinal diseases; and OcuLight TX, OcuLight SL, OcuLight SLx, OcuLight GL, and OcuLight GLx laser photocoagulation systems that are used to treat proliferative diabetic retinopathy, macular holes, retinal tears, and detachments. The company also provides delivery devices, including TxCell scanning laser delivery system that allows the physician to perform multi-spot pattern scanning; slit lamp adapter, which allows the physician to utilize a standard slit lamp in diagnosis and treatment procedures; and laser indirect ophthalmoscope for use in procedures to treat peripheral retinal disorders. It offers MicroPulse P3 Probe, which is used with its Cylco G6 laser system to perform MicroPulse transscleral laser therapy; G-Probe, which is used in procedures to treat uncontrolled glaucoma; G-Probe and G-Probe Illuminate, which are used in procedures to treat refractory glaucoma; and EndoProbe family of products for use in vitrectomy procedures. The company serves ophthalmologists, research and teaching hospitals, government installations, surgical centers, hospitals, veterinary practices, and office clinics. It markets its products through direct and independent sales force in the United States, as well as through independent distributors internationally. The company was formerly known as IRIS Medical Instruments, Inc. and changed its name to IRIDEX Corporation in November 1995. IRIDEX Corporation was incorporated in 1989 and is headquartered in Mountain View, California.

Price of IRIX

IRIX FAQ

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

IRIX Earnings Table

Unit : USD

QTRNon-GAAP EPSEPS YoYEPS Surprise %SalesSales YoYSales Surprise %NPM
Current
2025Q4
2025Q3
2025Q2
2025Q1
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-0.30
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
0.48
PB Ratio
269.77
Price-to-FCF
-
METRIC
VALUE
vs. INDUSTRY
Gross Margin
38.18%
Net Margin
-10.04%
Revenue Growth (YoY)
4.58%
Profit Growth (YoY)
2.85%
3-Year Revenue Growth
-5.16%
3-Year Profit Growth
-14.67%
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-0.30
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
0.48
PB Ratio
269.77
Price-to-FCF
-
Gross Margin
38.18%
Net Margin
-10.04%
Revenue Growth (YoY)
4.58%
Profit Growth (YoY)
2.85%
3-Year Revenue Growth
-5.16%
3-Year Profit Growth
-14.67%

  • When is IRIX's latest earnings report released?

    The most recent financial report for Iridex corporation (IRIX) covers the period of 2025Q3 and was published on 2025/09/27. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating IRIX's short-term business performance and financial health. For the latest updates on IRIX's earnings releases, visit this page regularly.

  • What is the operating profit of IRIX?

    According to the latest financial report, Iridex corporation (IRIX) reported an Operating Profit of -1.41M with an Operating Margin of -11.3% this period, representing a growth of 24.55% compared to the same period last year. Operating Profit reflects the company's core business efficiency and cost control, making it a key indicator for evaluating operational strength and profitability.

  • How is IRIX's revenue growth?

    In the latest financial report, Iridex corporation (IRIX) announced revenue of 12.48M, with a Year-Over-Year growth rate of 7.8%. Revenue growth can be driven by product mix changes, market share expansion, price adjustments, or international market penetration. Investors should also monitor gross margin and regional revenue distribution for a comprehensive view of growth quality and sustainability.

  • How much debt does IRIX have?

    As of the end of the reporting period, Iridex corporation (IRIX) had total debt of 4.79M, with a debt ratio of 0.17. Long-term debt comprises a higher/lower proportion. The level of financial leverage directly impacts the company's capital structure and interest coverage. If debt is high, pay attention to interest expenses and refinancing risks. Conversely, a low-leverage structure indicates greater risk tolerance but potentially less growth flexibility.

  • How much cash does IRIX have?

    At the end of the period, Iridex corporation (IRIX) held Total Cash and Cash Equivalents of 5.57M, accounting for 0.2 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.

  • Does IRIX go with three margins increasing?

    In the latest report, Iridex corporation (IRIX) did not achieve the “three margins increasing” benchmark, with a gross margin of 32.1%%, operating margin of -11.3%%, and net margin of -12.6%%. This demonstrates limited improvement in profitability, which is a key signal for fundamental analysis. Investors should consider margin trends alongside other financial indicators to assess IRIX's profit trajectory and future growth potential.

  • Is IRIX's EPS continuing to grow?

    According to the past four quarterly reports, Iridex corporation (IRIX)'s earnings per share (EPS) shows a steady growth trend, with the latest EPS at -0.09. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.

  • What is the FCF of IRIX?

    Iridex corporation (IRIX)'s Free Cash Flow (FCF) for the period is -1.17M, calculated as Operating Cash Flow minus Capital Expenditures, representing a rise of 61.91% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.